Experienced in Marginal Zone Lymphoma (MZL)

Chunyan H. Ji

Shandong Key Laboratory Of Hematological Diseases And Immune Microenvironment, 
Jinan, CN 
Experienced in Marginal Zone Lymphoma (MZL)
Shandong Key Laboratory Of Hematological Diseases And Immune Microenvironment, 
Jinan, CN 
OverviewLocationsClinical Research

Overview

Chunyan Ji practices in Jinan, China. Ji is rated as an Experienced expert by MediFind in the treatment of Marginal Zone Lymphoma (MZL). Their top areas of expertise are Acute Myeloid Leukemia (AML), Leukemia, Acute Lymphoblastic Leukemia (ALL), and Adult T-Cell Leukemia.

Their clinical research consists of co-authoring 101 peer reviewed articles and participating in 1 clinical trial. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article in the study of Marginal Zone Lymphoma (MZL).

Locations

Shandong Key Laboratory Of Hematological Diseases And Immune Microenvironment, Jinan, China
Other Locations
Qingdao, 266035, China
China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

1 Clinical Trials

A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
A Multicenter, Open-label, Phase 1/2a Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drugs: TJ011133, Azacitidine
Study Phase: Phase 1/Phase 2

101 Total Publications

Correction: Genetic polymorphisms in cGAS-STING-mediated type I interferon innate immune signaling pathway are associated with DLBCL.
Correction: Genetic polymorphisms in cGAS-STING-mediated type I interferon innate immune signaling pathway are associated with DLBCL.
Journal: Frontiers in immunology
Published: December 22, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ji's expertise for a condition
ConditionClose
      View All 18 Experienced Conditions
      Want to save this expert for later?
      Sign Up
      Not sure about your diagnosis?
      Check Your Symptoms
       
       
       
       
      Learn about our expert tiers
      Learn More
      Are you the provider on this profile?
      Claim Profile